Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...